A new trading day began on Monday, with Intellia Therapeutics Inc (NASDAQ: NTLA) stock price down -7.56% from the previous day of trading, before settling in for the closing price of $10.32. NTLA’s price has ranged from $9.25 to $34.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 4.71% over the past five years. Meanwhile, its annual earnings per share averaged 1.99%. With a float of $99.72 million, this company’s outstanding shares have now reached $101.80 million.
Let’s look at the performance matrix of the company that is accounted for 526 employees. In terms of profitability, gross margin is 82.41%, operating margin of -1247.99%, and the pretax margin is -1212.19%.
Intellia Therapeutics Inc (NTLA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 2.09%, while institutional ownership is 91.52%. The most recent insider transaction that took place on Jan 29 ’25, was worth 2,642. In this transaction Director of this company sold 265 shares at a rate of $9.97, taking the stock ownership to the 19,468 shares. Before that another transaction happened on Jan 03 ’25, when Company’s VP, Chief Accounting Officer sold 1,372 for $12.18, making the entire transaction worth $16,711. This insider now owns 45,640 shares in total.
Intellia Therapeutics Inc (NTLA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.76% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Here are Intellia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.33 in the next quarter and is forecasted to reach -5.13 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 2.62 million, a negative change from its year-to-date volume of 3.14 million. As of the previous 9 days, the stock’s Stochastic %D was 35.40%. Additionally, its Average True Range was 0.76.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 2.00%, which indicates a significant decrease from 13.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.16% in the past 14 days, which was lower than the 74.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.35, while its 200-day Moving Average is $19.51. Nevertheless, the first resistance level for the watch stands at $9.85 in the near term. At $10.17, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.43. If the price goes on to break the first support level at $9.27, it is likely to go to the next support level at $9.01. The third support level lies at $8.69 if the price breaches the second support level.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
With a market capitalization of 971.64 million, the company has a total of 101,849K Shares Outstanding. Currently, annual sales are 36,280 K while annual income is -481,190 K. The company’s previous quarter sales were 9,110 K while its latest quarter income was -135,710 K.
